daraxonrasib early – An experimental pancreatic cancer drug, daraxonrasib, received FDA approval to begin an early access program on April 30, triggering a surge of patient requests at cancer clinics. While late trial results showed median survival of 13.2 months versus 6.7 months
On April 30. the Food and Drug Administration allowed the experimental pancreatic cancer drug daraxonrasib to enter an early access program for some patients. By the time the news hit clinics. the waiting list had already become the story—doctors describe an influx of requests they are struggling to process.
Daraxonrasib targets a gene mutation behind most pancreatic cancer diagnoses. It is being rolled out through an expanded access pathway for patients whose disease has spread. as the drugmaker Revolution Medicines prepares for full FDA approval. The early access approval has provided a route to treatment before final clearance—but it has also exposed how quickly desperation can overwhelm even well-organized cancer centers.
Doctors say the demand is not theoretical. “The public caught wind of the FDA announcement… which has triggered a deluge of patient requests,” Dr. Daniel King, a medical oncologist at the Zuckerberg Cancer Center of Northwell Health, told Reuters. “Cancer centers are all figuring out how to engage with our own institutions, opening up the protocols to provide access.”.
Pancreatic cancer remains among the deadliest cancers. with only 3% of people surviving five years after diagnosis if the disease has spread to distant parts of the body. according to the National Cancer Institute. The American Cancer Society estimates that 67. 000 people in the United States will be diagnosed with pancreatic cancer this year. and 53. 000 will die.
The drug is once-daily and comes as a tablet. Revolution Medicines, the developer, says clinical trial results released in April showed patients who took daraxonrasib lived a median of 13.2 months—nearly double the median 6.7 months reported for patients who received standard chemotherapy.
The science is sharply focused. Over 90% of patients diagnosed with pancreatic cancer have a mutation in a gene called KRAS, Dr. Christopher Lieu. an oncologist and professor at the University of Colorado Anschutz Medical School’s Department of Medicine. previously told USA TODAY. Lieu described the mechanism this way: “The drug binds to the activating pocket of (the gene mutation) and shuts it down. It’s almost like if you have a bullhorn and you cover it up so no sound can escape.” He added: “There’s a possibility that this targeted therapy for pancreatic cancer could work more effectively than chemotherapy. meaning it could be a treatment with potentially less toxicity.”.
Daraxonrasib is still undergoing FDA review for full approval. The agency granted Revolution Medicines permission for a limited rollout through the expanded access program in late April. allowing the drugmaker to provide medication for free to some patients who have previously been treated for pancreatic cancer that has since spread to other parts of the body.
Under the FDA’s new. expedited drug review protocol. daraxonrasib could receive full approval as quickly as a month or two after a formal application is filed—faster than the agency’s typical 10 to 12 months. Revolution Medicines has not yet filed the application. but it said during an early May call that there is a “full-throttle effort” to do so. according to Reuters.
So who gets access—and what does that process look like when the demand is surging?
The FDA’s expanded access program was approved specifically for patients who have previously undergone treatment for pancreatic cancer that has metastasized. A licensed treating physician must submit a request to Revolution Medicines. After that, an institutional review board reviews the request. The company said it expects to respond to requests within two business days of receipt.
If the company approves the request as a good fit for the patient, the information is then submitted to the FDA. Patients are followed by hospital monitoring boards, and serious side effects or other issues must be reported to both Revolution Medicines and the FDA.
Doctors and patients are also navigating a shifting regulatory backdrop. The expedited voucher program that allowed this early access was touted as an accomplishment of former FDA Commissioner Dr. Marty Makary, who resigned May 12. No intended changes to the program have been communicated.
Clinics weren’t expecting the volume. Reuters reported May 14 that cancer clinics were bombarded with requests to join the expanded access program. Doctors told the outlet demand is already high and expected to continue growing.
The political and personal stakes around the drug have been underscored by high-profile testimony. Former Republican Sen. Ben Sasse told “60 Minutes” host Scott Pelley in April that daraxonrasib is a “miracle drug” that has helped him manage his pancreatic cancer, which spread to his lung and liver.
“I have much, much less pain than I had four months ago when I was diagnosed, and I have a massive 76% reduction in tumor volume over the last four months,” Sasse said during the interview. “So maybe I’m going to crank and live a year instead of a handful of months.”
Sasse said doctors initially gave him three to four months to live upon diagnosis in December, but he described having more time after treatment, crediting “providence, prayer, and a miracle drug.”
Even with the clinical data pointing to longer survival for some patients. the approval process still runs through FDA review and formal applications. For now. the drug exists in two worlds at once: carefully controlled access under FDA expanded rules. and a broader public waiting for full approval while clinics work to keep up with requests that have arrived faster than most treatment systems are built to handle.
daraxonrasib pancreatic cancer FDA early access expanded access program Revolution Medicines KRAS mutation chemotherapy expedited drug review Daniel King Christopher Lieu Ben Sasse